{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T01:30:16Z","timestamp":1780450216957,"version":"3.54.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Spine Journal"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.spinee.2013.09.056","type":"journal-article","created":{"date-parts":[[2013,12,14]],"date-time":"2013-12-14T19:30:21Z","timestamp":1387049421000},"page":"560-565","source":"Crossref","is-referenced-by-count":11,"title":["Postmarketing safety of biologics and biological devices"],"prefix":"10.1016","volume":"14","author":[{"given":"Emily Jane","family":"Woo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.spinee.2013.09.056_bib1","doi-asserted-by":"crossref","first-page":"260","DOI":"10.5435\/00124635-200805000-00004","article-title":"The FDA process for the evaluation and approval of orthopaedic devices","volume":"16","author":"Kirkpatrick","year":"2008","journal-title":"J Am Acad Orthop Surg"},{"key":"10.1016\/j.spinee.2013.09.056_bib2","unstructured":"U.S. Food and Drug Administration. Manufacturer and User Facility Device Experience Database - (MAUDE). Available at: http:\/\/www.fda.gov\/MedicalDevices\/DeviceRegulationandGuidance\/PostmarketRequirements\/ReportingAdverseEvents\/ucm127891.htm. Accessed August 23,\u00a02013."},{"key":"10.1016\/j.spinee.2013.09.056_bib3","unstructured":"U.S. Food and Drug Administration. MedWatch: The FDA Safety Information and Adverse Event Reporting Program. Available at: http:\/\/www.fda.gov\/Safety\/MedWatch\/default.htm. Accessed August 23, 2013."},{"key":"10.1016\/j.spinee.2013.09.056_bib4","unstructured":"U.S. Food and Drug Administration. Guidance for Industry: MedWatch Form FDA 3500A: Mandatory Reporting of Adverse Reactions Related to Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT\/Ps). Available at: http:\/\/www.fda.gov\/BiologicsBloodVaccines\/GuidanceComplianceRegulatoryInformation\/Guidances\/Tissue\/ucm074000.htm. Accessed August 23,\u00a02013."},{"key":"10.1016\/j.spinee.2013.09.056_bib5","unstructured":"U.S. Food and Drug Administration. FDA Adverse Event Reporting System (FAERS) (formerly AERS). Available at: http:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Surveillance\/AdverseDrugEffects\/default.htm. Accessed August 23,\u00a02013."},{"key":"10.1016\/j.spinee.2013.09.056_bib6","unstructured":"Code of Federal Regulations. 21 CFR 600.80."},{"key":"10.1016\/j.spinee.2013.09.056_bib7","unstructured":"U.S. Food and Drug Administration. Human Cell & Tissue Products (HCT\/P) Adverse Reaction Reporting. Available at: http:\/\/www.fda.gov\/BiologicsBloodVaccines\/SafetyAvailability\/ReportaProblem\/ucm152576.htm. Accessed August 23,\u00a02013."},{"key":"10.1016\/j.spinee.2013.09.056_bib8","unstructured":"Code of Federal Regulations. 21 CFR 1271.350 (a)."},{"key":"10.1016\/j.spinee.2013.09.056_bib9","unstructured":"U.S. Food and Drug Administration. FDA Regulation of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT\/P's) Product List. Available at: http:\/\/www.fda.gov\/BiologicsBloodVaccines\/TissueTissueProducts\/RegulationofTissues\/ucm150485.htm. Accessed August 23,\u00a02013."},{"key":"10.1016\/j.spinee.2013.09.056_bib10","first-page":"295","article-title":"The environment and disease: association or causation?","volume":"58","author":"Hill","year":"1965","journal-title":"Proc R Soc Med"},{"key":"10.1016\/j.spinee.2013.09.056_bib11","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.2105\/AJPH.85.12.1706","article-title":"The reporting sensitivities of two passive surveillance systems for vaccine adverse events","volume":"85","author":"Rosenthal","year":"1995","journal-title":"Am J Public Health"},{"key":"10.1016\/j.spinee.2013.09.056_bib12","unstructured":"U.S. Food and Drug Administration FDA Public Health Notification: Life-threatening Complications Associated with Recombinant Human Bone Morphogenetic Protein in Cervical Spine Fusion. Available at: http:\/\/www.fda.gov\/medicaldevices\/safety\/alertsandnotices\/publichealthnotifications\/ucm062000.htm. Accessed August 23,\u00a02013."},{"key":"10.1016\/j.spinee.2013.09.056_bib13","unstructured":"INFUSE\u00ae Bone Graft\/LT-CAGE\u00ae Lumbar Tapered Fusion Device. INFUSE\u00ae Bone Graft\/INTER FIX\u2122 Threaded Fusion Device. INFUSE\u00ae Bone Graft\/INTER FIX\u2122 RP Threaded Fusion Device - Reduced Profile. Available at: https:\/\/www.infusebonegraft.com\/spine_package_insert.pdf. Accessed August 23,\u00a02013."},{"key":"10.1016\/j.spinee.2013.09.056_bib14","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.spinee.2012.09.052","article-title":"Recombinant human bone morphogenetic protein 2: adverse events reported to the manufacturer and user facility device experience database","volume":"12","author":"Woo","year":"2012","journal-title":"Spine J"},{"key":"10.1016\/j.spinee.2013.09.056_bib15","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1007\/s11999-012-2684-x","article-title":"Adverse events after recombinant human BMP2 in nonspinal orthopaedic procedures","volume":"471","author":"Woo","year":"2013","journal-title":"Clin Orthop Relat Res"},{"key":"10.1016\/j.spinee.2013.09.056_bib16","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.spinee.2012.01.017","article-title":"Dural repair with spinal sealants","volume":"12","author":"Woo","year":"2012","journal-title":"Spine J"},{"key":"10.1016\/j.spinee.2013.09.056_bib17","unstructured":"U.S. Food and Drug Administration. FDA Safety Notification: Risk of Life-Threatening Air or Gas Embolism with the Use of Spray Devices Employing Pressure Regulator to Administer Fibrin Sealants - Evicel. Available at: http:\/\/www.fda.gov\/BiologicsBloodVaccines\/BloodBloodProducts\/ApprovedProducts\/LicensedProductsBLAs\/FractionatedPlasmaProducts\/ucm219997.htm. Accessed August 23,\u00a02013."},{"key":"10.1016\/j.spinee.2013.09.056_bib18","unstructured":"U.S. Food and Drug Administration. Risk of Life-Threatening Air or Gas Embolism with the Use of Spray Devices Employing Pressure Regulator to Administer Fibrin Sealants (Baxter Healthcare Corporation). Available at: http:\/\/www.fda.gov\/BiologicsBloodVaccines\/SafetyAvailability\/ucm209778.htm. Accessed August 23,\u00a02013."},{"key":"10.1016\/j.spinee.2013.09.056_bib19","unstructured":"U.S. Food and Drug Administration. FDA Safety Notification: Risk of Air or Gas Embolism When Using Air- or Gas- Pressurized Spray Devices. Available at: http:\/\/www.fda.gov\/MedicalDevices\/Safety\/AlertsandNotices\/ucm218523.htm. Accessed August 23,\u00a02013."},{"key":"10.1016\/j.spinee.2013.09.056_bib20","unstructured":"U.S. Food and Drug Administration. April 2010 Drug Safety Labeling Changes. Available at: http:\/\/www.fda.gov\/Safety\/MedWatch\/SafetyInformation\/ucm209165.htm. Accessed August 23,\u00a02013."},{"key":"10.1016\/j.spinee.2013.09.056_bib21","unstructured":"U.S. Food and Drug Administration. Potential Signals of Serious Risks\/New Safety Information Identified by the Adverse Event Reporting System (AERS) between January - March 2011. Available at: http:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Surveillance\/AdverseDrugEffects\/ucm258366.htm. Accessed August 23,\u00a02013."},{"key":"10.1016\/j.spinee.2013.09.056_bib22","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s10561-011-9253-5","article-title":"Reported infections after human tissue transplantation before and after new Food and Drug Administration (FDA) regulations, United States, 2001 through June, 2010","volume":"13","author":"Mallick","year":"2012","journal-title":"Cell Tissue Bank"},{"key":"10.1016\/j.spinee.2013.09.056_bib23","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s10561-007-9034-3","article-title":"Infections and human tissue transplants: review of FDA MedWatch reports 2001\u20132004","volume":"8","author":"Wang","year":"2007","journal-title":"Cell Tissue Bank"},{"key":"10.1016\/j.spinee.2013.09.056_bib24","unstructured":"U.S. Food and Drug Administration. Postmarket Drug and Biologic Safety Evaluations. Available at: http:\/\/www.fda.gov\/drugs\/guidancecomplianceregulatoryinformation\/surveillance\/ucm204091.htm. Accessed August 23,\u00a02013."},{"key":"10.1016\/j.spinee.2013.09.056_bib25","unstructured":"U.S. Food and Drug Administration. Potential Signals of Serious Risks\/New Safety Information Identified from the FDA Adverse Event Reporting System (FAERS) (formerly AERS). Available at: http:\/\/www.fda.gov\/drugs\/guidanceComplianceRegulatoryInformation\/Surveillance\/AdverseDrugEffects\/ucm082196.htm. Accessed August 23, 2013."},{"key":"10.1016\/j.spinee.2013.09.056_bib26","unstructured":"U.S. Food and Drug Administration. Questions and Answers on the Federal Register Notice on Drugs and Biological Products Deemed to Have Risk Evaluation and Mitigation Strategies. Available at: http:\/\/www.fda.gov\/RegulatoryInformation\/Legislation\/FederalFoodDrugandCosmeticActFDCAct\/SignificantAmendmentstotheFDCAct\/FoodandDrugAdministrationAmendmentsActof2007\/ucm095439.htm. Accessed August 23,\u00a02013."},{"key":"10.1016\/j.spinee.2013.09.056_bib27","unstructured":"U.S. Food and Drug Administration. Postmarketing Requirements and Commitments: Legislative Background. Available at: http:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Post-marketingPhaseIVCommitments\/ucm064633.htm. Accessed August 23, 2013."},{"key":"10.1016\/j.spinee.2013.09.056_bib28","unstructured":"U.S. Food and Drug Administration. Post approval studies. Available at: http:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfPMA\/pma_pas.cfm. Accessed August 23,\u00a02013."},{"key":"10.1016\/j.spinee.2013.09.056_bib29","unstructured":"U.S. Food and Drug Administration. FDAAA Implementation - Highlights Two Years After Enactment. Available at: http:\/\/www.fda.gov\/RegulatoryInformation\/Legislation\/FederalFoodDrugandCosmeticActFDCAct\/SignificantAmendmentstotheFDCAct\/FoodandDrugAdministrationAmendmentsActof2007\/ucm184271.htm. Accessed August 23,\u00a02013."},{"key":"10.1016\/j.spinee.2013.09.056_bib30","unstructured":"U.S. Food and Drug Administration. FDA's Sentinel Initiative - Ongoing Projects. Available at: http:\/\/www.fda.gov\/Safety\/FDAsSentinelInitiative\/ucm203500.htm. Accessed August 23,\u00a02013."},{"key":"10.1016\/j.spinee.2013.09.056_bib31","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJMp1302834","article-title":"Dabigatran and postmarketing reports of bleeding","volume":"368","author":"Southworth","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.spinee.2013.09.056_bib32","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1001\/jamainternmed.2013.3004","article-title":"Rapid assessment of cardiovascular risk among users of smoking cessation drugs within the US Food and Drug Administration's Mini-Sentinel program","volume":"173","author":"Toh","year":"2013","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.spinee.2013.09.056_bib33","doi-asserted-by":"crossref","first-page":"193","DOI":"10.5435\/00124635-201004000-00002","article-title":"Reporting and notification of adverse events in orthopaedics","volume":"18","author":"Mihalko","year":"2010","journal-title":"J Am Acad Orthop Surg"},{"key":"10.1016\/j.spinee.2013.09.056_bib34","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.spinee.2011.04.023","article-title":"A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned","volume":"11","author":"Carragee","year":"2011","journal-title":"Spine J"},{"key":"10.1016\/j.spinee.2013.09.056_bib35","unstructured":"FDA Public Health Notification: Life-threatening Complications Associated with Recombinant Human Bone. Morphogenetic Protein in Cervical Spine Fusion. Available at: http:\/\/www.spine.org\/Documents\/rhBMP_cervical_7-08_rev%20_2_.pdf. Accessed August 23,\u00a02013."}],"container-title":["The Spine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1529943013019839?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1529943013019839?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,8]],"date-time":"2018-10-08T06:20:49Z","timestamp":1538979649000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1529943013019839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S1529943013019839"],"URL":"https:\/\/doi.org\/10.1016\/j.spinee.2013.09.056","relation":{},"ISSN":["1529-9430"],"issn-type":[{"value":"1529-9430","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]}}}